Elizabeth A Thomas

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10667781/publications.pdf

Version: 2024-02-01

70 papers	4,054 citations	109321 35 h-index	118850 62 g-index
70 all docs	70 docs citations	70 times ranked	5842 citing authors

#	Article	IF	Citations
1	Salivary S100 calcium-binding protein beta (S100B) and neurofilament light (NfL) after acute exposure to repeated head impacts in collegiate water polo players. Scientific Reports, 2022, 12, 3439.	3.3	5
2	Associations between prognostic index scores and plasma neurofilament light in Huntington's disease. Parkinsonism and Related Disorders, 2022, 97, 25-28.	2.2	6
3	Plasma neurofilament light in Huntington's disease: A marker for disease onset, but not symptom progression. Parkinsonism and Related Disorders, 2021, 87, 32-38.	2.2	19
4	Saliva testing as a means to monitor therapeutic lithium levels in patients with psychiatric disorders: Identification of clinical and environmental covariates, and their incorporation into a prediction model. Bipolar Disorders, 2021, 23, 679-688.	1.9	14
5	Levels of Interleukin-6 in Saliva, but Not Plasma, Correlate with Clinical Metrics in Huntingtonâ€™s Disease Patients and Healthy Control Subjects. International Journal of Molecular Sciences, 2020, 21, 6363.	4.1	27
6	Reducing Mcl-1 gene dosage induces dopaminergic neuronal loss and motor impairments in Park2 knockout mice. Communications Biology, 2019, 2, 125.	4.4	11
7	Epigenetic mechanisms in Huntington's disease. , 2019, , 73-95.		3
8	Evaluation of Biochemical and Epigenetic Measures of Peripheral Brain-Derived Neurotrophic Factor (BDNF) as a Biomarker in Huntingtonâ€™s Disease Patients. Frontiers in Molecular Neuroscience, 2019, 12, 335.	2.9	41
9	Complex neuroprotective and neurotoxic effects of histone deacetylases. Journal of Neurochemistry, 2018, 145, 96-110.	3.9	55
10	Salivary levels of total huntingtin are elevated in Huntingtonâ€™s disease patients. Scientific Reports, 2018, 8, 7371.	3.3	25
11	Histone Posttranslational Modifications in Schizophrenia. Advances in Experimental Medicine and Biology, 2017, 978, 237-254.	1.6	26
12	Beneficial effects of glatiramer acetate in Huntingtonâ€™s disease mouse models: Evidence for BDNF-elevating and immunomodulatory mechanisms. Brain Research, 2017, 1673, 102-110.	2.2	16
13	The Role of Histone Deacetylase Inhibition in the Accumulation and Stability of Disease-Related Proteins. , 2017, , 159-179.		3
14	The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntingtonâ€™s Disease Mice. PLoS ONE, 2016, 11, e0152498.	2.5	73
15	Increased cortical expression of the zinc transporter SLC39A12 suggests a breakdown in zinc cellular homeostasis as part of the pathophysiology of schizophrenia. NPJ Schizophrenia, 2016, 2, 16002.	3.6	47
16	DNA methylation in Huntingtonâ€™s disease: Implications for transgenerational effects. Neuroscience Letters, 2016, 625, 34-39.	2.1	33
17	HDAC inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E56-64.	7.1	95
18	Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease. Journal of Huntington's Disease, 2014, 3, 311-316.	1.9	12

#	Article	IF	Citations
19	Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors. Pharmaceuticals, 2014, 7, 634-661.	3.8	34
20	Behavioral and transcriptome alterations in male and female mice with postnatal deletion of TrkB in dorsal striatal medium spiny neurons. Molecular Neurodegeneration, 2013, 8, 47.	10.8	11
21	Epigenetic changes at gene promoters in response to immune activation in utero. Brain, Behavior, and Immunity, 2013, 30, 168-175.	4.1	78
22	Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitinâ€“proteasomal and autophagy systems. Human Molecular Genetics, 2012, 21, 5280-5293.	2.9	128
23	Egr-1 Induces DARPP-32 Expression in Striatal Medium Spiny Neurons via a Conserved Intragenic Element. Journal of Neuroscience, 2012, 32, 6808-6818.	3.6	21
24	Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease. Human Molecular Genetics, 2012, 21, 3097-3111.	2.9	55
25	Differential age- and disease-related effects on the expression of genes related to the arachidonic acid signaling pathway in schizophrenia. Psychiatry Research, 2012, 196, 201-206.	3.3	34
26	Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease. Neurobiology of Disease, 2012, 46, 351-361.	4.4	157
27	Sphingolipid abnormalities in psychiatric disorders: a missing link in pathology?. Frontiers in Bioscience - Landmark, 2011, 16, 1797.	3.0	24
28	Gene expression profiling of R6/2 transgenic mice with different CAG repeat lengths reveals genes associated with disease onset and progression in Huntington's disease. Neurobiology of Disease, 2011, 42, 459-467.	4.4	63
29	Phospholipase C Beta 1 Expression in the Dorsolateral Prefrontal Cortex from Patients with Schizophrenia at Different Stages of Illness. Australian and New Zealand Journal of Psychiatry, 2011, 45, 140-147.	2.3	29
30	In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons. Human Molecular Genetics, 2011, 20, 1049-1060.	2.9	56
31	Changes in Gene Expression in Subjects with Schizophrenia Associated with Disease Progression. , 2011, , 237-251.		1
32	Genome-Wide Identification of Bcl11b Gene Targets Reveals Role in Brain-Derived Neurotrophic Factor Signaling. PLoS ONE, 2011, 6, e23691.	2.5	53
33	Cerebellar lipid differences between R6/1 transgenic mice and humans with Huntingtonâ€™s disease. Journal of Neurochemistry, 2010, 115, 748-758.	3.9	36
34	Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nature Neuroscience, 2010, 13, 1113-1119.	14.8	534
35	Low density lipoprotein receptor-related protein and apolipoprotein E expression is altered in schizophrenia. Frontiers in Psychiatry, 2010, 1, 19.	2.6	12
36	Coexpression network analysis of neural tissue reveals perturbations in developmental processes in schizophrenia. Genome Research, 2010, 20, 403-412.	5.5	127

#	Article	IF	Citations
37	A role of apolipoprotein D in triglyceride metabolism. Journal of Lipid Research, 2010, 51, 1298-1311.	4.2	59
38	Evidence for disruption of sphingolipid metabolism in schizophrenia. Journal of Neuroscience Research, 2009, 87, 278-288.	2.9	85
39	Focal Nature of Neurological Disorders Necessitates Isotype-Selective Histone Deacetylase (HDAC) Inhibitors. Molecular Neurobiology, 2009, 40, 33-45.	4.0	50
40	Normal human aging and earlyâ€stage schizophrenia share common molecular profiles. Aging Cell, 2009, 8, 339-342.	6.7	41
41	Apolipoprotein D mRNA expression is elevated in PDAPP transgenic mice. Journal of Neurochemistry, 2008, 79, 1059-1064.	3.9	25
42	Molecular profiles of schizophrenia in the CNS at different stages of illness. Brain Research, 2008, 1239, 235-248.	2.2	178
43	Functional roles for the striatal-enriched transcription factor, Bcl11b, in the control of striatal gene expression and transcriptional dysregulation in Huntington's disease. Neurobiology of Disease, 2008, 31, 298-308.	4.4	63
44	The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 15564-15569.	7.1	271
45	Regulator of G-Protein Signalling 4 Expression is Not Altered in the Prefrontal Cortex in Schizophrenia. Australian and New Zealand Journal of Psychiatry, 2008, 42, 740-745.	2.3	12
46	Gene Expression Profiling in Brodmann's Area 46 from Subjects with Schizophrenia. Australian and New Zealand Journal of Psychiatry, 2007, 41, 308-320.	2.3	74
47	Clozapine specifically alters the arachidonic acid pathway in mice lacking apolipoprotein D. Schizophrenia Research, 2007, 89, 147-153.	2.0	23
48	Chronic haloperidol treatment results in a decrease in the expression of myelin/oligodendrocyte-related genes in the mouse brain. Journal of Neuroscience Research, 2007, 85, 757-765.	2.9	52
49	Glycolipid and ganglioside metabolism imbalances in Huntington's disease. Neurobiology of Disease, 2007, 27, 265-277.	4.4	120
50	Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. Journal of Neurochemistry, 2006, 96, 743-757.	3.9	125
51	Molecular Profiling of Antipsychotic Drug Function: Convergent Mechanisms in the Pathology and Treatment of Psychiatric Disorders. Molecular Neurobiology, 2006, 34, 109-128.	4.0	35
52	Striatal specificity of gene expression dysregulation in Huntington's disease. Journal of Neuroscience Research, 2006, 84, 1151-1164.	2.9	53
53	Association of plasma apolipoproteins D with RBC membrane arachidonic acid levels in schizophrenia. Schizophrenia Research, 2005, 72, 259-266.	2.0	19
54	Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimerâ€™s disease. Biological Psychiatry, 2003, 54, 136-141.	1.3	51

#	Article	IF	Citations
55	Apolipoprotein D modulates arachidonic acid signaling in cultured cells: implications for psychiatric disorders. Prostaglandins Leukotrienes and Essential Fatty Acids, 2003, 69, 421-427.	2.2	34
56	Increased levels of apolipoprotein E in the frontal cortex of subjects with schizophrenia. Biological Psychiatry, 2003, 54, 616-622.	1.3	41
57	Novel Isoform of Insulin Receptor Substrate p53/p58 Is Generated by Alternative Splicing in the CRIB/SH3-binding Region. Journal of Biological Chemistry, 2002, 277, 24728-24734.	3.4	21
58	Evolutionarily Distinct Classes of S27 Ribosomal Proteins with Differential mRNA Expression in Rat Hypothalamus. Journal of Neurochemistry, 2002, 74, 2259-2267.	3.9	26
59	The Endogenous Lipid Oleamide Activates Serotonin 5-HT7 Neurons in Mouse Thalamus and Hypothalamus. Journal of Neurochemistry, 2002, 72, 2370-2378.	3.9	40
60	The Neurobiology of Apolipoproteins in Psychiatric Disorders. Molecular Neurobiology, 2002, 26, 369-388.	4.0	32
61	Insulin receptor substrate protein p53 localization in rats suggests mechanism for specific polyglutamine neurodegeneration. Neuroscience Letters, 2001, 309, 145-148.	2.1	17
62	Clozapine increases apolipoprotein D expression in rodent brain: towards a mechanism for neuroleptic pharmacotherapy. Journal of Neurochemistry, 2001, 76, 789-796.	3.9	60
63	Pertussis toxin treatment prevents 5-HT5a receptor-mediated inhibition of cyclic AMP accumulation in rat C6 glioma cells. Journal of Neuroscience Research, 2000, 61, 75-81.	2.9	24
64	Allosteric regulation by oleamide of the binding properties of 5-hydroxytryptamine7 receptors. Biochemical Pharmacology, 1999, 58, 1807-1813.	4.4	54
65	RGS9: A regulator of G-protein signalling with specific expression in rat and mouse striatum. Journal of Neuroscience Research, 1998, 52, 118-124.	2.9	76
66	Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system. Journal of Neuroscience Research, 1997, 50, 1047-1052.	2.9	162
67	Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system. Journal of Neuroscience Research, 1997, 50, 1047-1052.	2.9	3
68	Involvement of the M2 muscarinic receptor in contractions of the guinea pig trachea, guinea pig esophagus, and rat fundus. Biochemical Pharmacology, 1996, 51, 779-788.	4.4	40
69	The 5-HT5A serotonin receptor is expressed predominantly by astrocytes in which it inhibits cAMP accumulation: A mechanism for neuronal suppression of reactive astrocytes. , 1996, 17, 317-326.		87
70	Functional role of M2 muscarinic receptors in the guinea pig ileum. Life Sciences, 1995, 56, 965-971.	4.3	37